Sandbox: STEMI

Jump to navigation Jump to search

2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-segment Elevation

Changes in Recommendations

What is new in 2017 Guidelines on AMI-STEMI?

2012 2017
IIa - Radial access I - Radial access (MATRIX)
IIa - DES over BMS I - DES over BMS (EXAMINATION, COMFORTABLE-AMI, NORSTENT)
III - Complete Revascularization IIa - Complete Revascularization (PRAMI, DANAMI-3-PRIMULTI, CVLPRIT, Compare-Acute)
IIa - Complete Revascularization III - Thrombus Aspiration (TOTAL, TASTE)
I - Bivalirudin IIa -Bivalirudin (MATRIX, HEAT-PPCI)
IIb - Enoxaparin IIa - Enoxaparin (ATOLL, Meta-analysis)
IIb - Early Hospital Discharge IIa - Early Hospital Discharge (Small trials & observational data)
I - (Oxygen when SaO2 <95%) OXYGEN I - OXYGEN (Oxygen when SaO2 <90%) AVOID, DETO2X
(Same dose i.V in all patients) TNK-tPA TNK-tPA (Half dose i.V. in Pts ≥75 years, STREAM)

AMI-STEMI - 2017 NEW RECOMMENDATIONS

IIa - Additional lipid lowering therapy if LDL >1.8 mmol/L (70 mg/dL) despite on maximum tolerated statins. IMPROVE-IT, FOURIER IIa - Complete revascularization during index primary PCI in STEMI patients in shock. (Expert opinion)
IIb - 1) Cangrelor if P2Y12 inhibitors have not been given. (CHAMPION) 2) Switch to potent P2Y12 inhibitors 48 hours after fibrinolysis. (Expert opinion) 3)Extend Ticagrelor up to 36 months in high-risk patients. (PEGASUS-TIMI 54) 4)Use of polypill to increase adherence. (FOCUS)
III - Routine use of deferred stenting. DANAMI 3-DEFER